Purpose: Lymphoproliferative neoplasms are the largest and most frequently diagnosed entities in the group of haema tological malignancies. The aim of the study was to assess whether apparent diffusion coefficient (ADC) measured on the first day of the second cycle of chemotherapy could be a predictor of prognosis and of the final treatment's outcome.
Results:
The difference between ADC values in pretreatment (ADC = 720 mm Conclusions: ADC measurement's before treatment and on the first day of the second cycle of chemotherapy can be used as a prognostic marker in lymphoma therapy. ADC values lower than 1080 mm 2 /s and an increase of the ratio after the treatment can be considered as a marker of disease progression.
Introduction
Lymphoproliferative neoplasms are the largest and most frequently diagnosed entities in the group of haematolog ical malignancies [1] staging, and response assessment of patients with Hodgkin lymphoma (HL). Over the years an increasing trend of incidence rate of lymphomas has been noticed. Currently it amounts to approximately 2022 new cases per 100,000 persons per year, according to various regi sters [2, 3] .
Introducing new diagnostic tools to everyday prac tice allows more precise evaluation of disease. One of the most important aspects is the evaluation of response to treatment. Accurate assessment of early response is crucial to the diagnosis of lymphoma. This allows patients to be distinguished within the highrisk groups and to modi fy ineffective treatment in the early stages. This is of ut most importance in the context of individualisation and optimisation of treatment, contributing to positive effects for both the patients and for the entire health care system (economic effect).
Positron emission tomography computed tomog raphy (PET/CT) scanning is currently considered to be the reference method for the assessment of response in the majority of lymphomas, especially in the evaluation of early response to treatment in HL [4] who underwent both [ 18 F]FDGPET/CT and wholebody MRI (including T1 and diffusionweighted sequences). There are several studies describing the potential role of diffusion weight ed imaging (DWI) in the diagnosis and evaluation of re sponse to treatment of lymphomas [5] 31 females, medi an age -42 years, range 1586 years. DWI is a technique in which the image contrast reflects the in vivo changes in the motion of water molecules (Brownian motion) in tissues. A supplemental tool in DWI is the apparent diffusion coefficient (ADC) map, acquired by postpro cessing of the obtained DWI images [6] . ADC allows for quantitative definition of diffusion parameters (in mm 2 /s) ( Figure 1 ). The applicability of DWI has been confirmed e.g. in the detection of ischaemic stroke or in the evalua tion of breast or prostate gland abnormalities. Numerous recent studies associated with DWI have focused on uti lisation of its tools to evaluate response to treatment in oncological patients. Haematological diseases seem to be a very perspective area for the DWI tools, e.g. due to high cellularity of lymphoma infiltration [7] .
The purpose of this study was the assessment of the DWI/ADC imaging protocol in the evaluation of the ear ly response to treatment of Hodgkin's and nonHodgkin's lymphomas. Additionally, we analysed whether the ADC measured on the first day of the second cycle of chemo therapy could be a predictor of prognosis and of the final outcome of the treatment.
Material and methods
The study included the final group of 27 patients with Hodgkin's and nonHodgkin's lymphoma diagnosed (Table 1) . They underwent MRI of the area in question be fore the treatment and on the first day of the second cycle of chemotherapy. All examinations were performed using a 1.5 T MR unit with a conventional phased array body coil. The DWI was performed using a standard protocol, namely the singleshot spinechoplanar imaging (EPI) in the axial plane, with the following parameters: TR 5200 6000 ms, TE -72 ms, voxel size 2 × 2 × 5, Bw 1448 Hz/px, b values 50, 400, and 800, 3045 slices, duration ~6 min.
ADC maps were calculated with a dedicated work station. ADC values were measured in lymphoma infil tration in the area of the lowest signal in the ADC map images in posttreatment study, paying particular atten tion to avoid areas that could affect the DWI signal, e.g. haematomas. The corresponding area was determined in the pretreatment study, and the pretreatment ADC val ues were measured afterwards. Only ovalshaped ROIs were used to measure the ADC values, and the size thereof was adjusted to the size of the area with the lowest ADC signal. The ADC values were analysed as an independent value and as a ratio -dorsal muscles were used as the ref erence organs (Figure 2) . A Wilcoxon test was performed to verify the difference between the ADC values before and after the treatment. The ROC curve was used to determine the cutoff values, and the odds ratio was calculated.
Results
There was a statistically significant difference between the ADC values in the pretreatment (ADC = 720 mm 2 /s) and posttreatment (ADC = 1059 mm 2 /s) studies ( Figure 3 ). The ADC value increased significantly in both groups (Table 2, Figure 4 ). In the group of patients with diagnosed HL the ADC increased by 344 mm 2 /s on average, and by 206 mm 2 /s in patients with nonHodgkin's lymphoma, respectively. The cutoff values used for estimation of the response to the treatment were established at the level of ADC 1080 mm 2 /s, and the ADC to muscle ratio 0.82 in the posttreatment study ( Figure 3 ). The patients with ADC > 752 mm 2 /s before treatment demonstrated low er probability of progression than the patients with ADC < 752 mm 2 /s (p = 0.046). Considering the changes be tween the studies, an increase of the ADC by 34.5% and an increase of the ratio of by 32.5% were determined as the cutoff values. The highest odd ratios were calcu lated proving that the preexamination ADC or the ratio itself would serve best for an assessment of the low re sponse risk.
Discussion
Advanced imaging techniques play an important role in the diagnosis, evaluation, and staging of lymphomas [1] staging, and response assessment of patients with HL. De spite the fact that the sensitivity and specificity of PET/ CT with 18 FFDG depends on the histological lymphoma subtype, the Lugano classification of malignant lympho mas recommends the use of PET/CT with 18 FFDG as the reference imaging technique combined with bone mar row biopsy (BM) [1, 8] staging, and response assessment of patients with HL. There are several studies describing the role of wholebody MRI, with the DWI/ADC meas urement as a diagnostic tool in the evaluation of patients with lymphoma [912] metabolic tumor volume (MTV). The potential role of the measurements of DWI/ADC in patients with nonHodgkin's lymphoma was well de scribed in 2012 by Chen and Zhong. The authors reported that WBDWI can be adopted to detect morphological changes of lesions, but moreover it provides important functional information about the growth and decline pro cess of tumour cells [13] . The effectiveness of PETCT and MRI DWI/ADC in the initial stages of malignant lympho ma was analysed in another study. The authors compared these two methods in a pretherapeutic context and agree ment for Ann Arbor staging. They reported high repeat There were weak inversed correlations be tween the SUV max and ADC min in all cases, but it was not repeated in subgroups [9] MTV. The prognostic feature of the DWI/ADC was the subject of the study performed on the group of 28 patients with primary central nervous system lymphoma. It was investigated which DWI/ADC rank or parameter is a better biomarker of the response to treatment. It was revealed that DWI/ADC 5 th percentiles are good predictors for progressionfree survival.
The early response to treatment is an important in dicator of a patient's condition and prognosis [15] . Ap propriately quick assessment enables modification of the treatment protocol and if necessary adjustment to pa tient's needs. In this study we evaluated weather the ADC measured on the first day of the second cycle of chemo therapy could be a predictor of prognosis and of the final treatment's outcome. There was a statistically significant difference between the DWI/ADC values in groups with Hodgkin's and nonHodgkin's lymphomas. Patients with HL had higher values of DWI/ADC before and after the treatment (respectively, p = 0.027 and p = 0.029). Sim ilar results were obtained in other studies [1, 16, 17] i.e., indolent versus aggressive lymphoma, and also to assess the prognostic value of different quantitative parameters of wholebody. Our results indicated that patients with ADC > 752 mm 2 /s before treatment demonstrated low er probability of progression than the patients with ADC < 752 mm 2 /s (p = 0.046). Mosavi et al. similarly reported a significant relationship between higher mean ADC and longer overall survival (p = 0.006) [16] . An increase of the ADC by 34.5% after the second cycle of chemotherapy correlates with a better prognosis. This result has not been confirmed in other cancers. Multivariate analysis in head and neck cancer revealed that lower pretreatment ADC was associated with a better response to treatment [16] .
There were some limitations to this pilot study, such as the small number of patients with diagnosed nonHodg kin's lymphoma, or lack of histopathological results. 
Conclusions
Measurements of the ADC values before treatment and on the first day of the second cycle of chemotherapy can be used as a prognostic marker in the therapy of lympho mas. The most promising tool for assessing response to treatment seems to be the ratio between the ADC value measured in the area of infiltration and the ADC value of the reference organ (in our case -dorsal muscles). We calculated that an increase of the ratio lower than 32.5%
could serve as a poor prognostic factor and could lead to modification of treatment. Early DWI/ADC measure ments enable shortening of the diagnostic process, thus obtaining a quicker assessment of prognosis. An early re sponse to treatment can influence further therapy and can potentially increase the chances for regression of lympho ma. The results seem to be promising, but further studies with larger groups of patients and longterm followup are essential to prove the usefulness of the DWI/ADC meas urements in the evaluation of lymphoma.
